<SEC-DOCUMENT>0001062993-24-019855.txt : 20241202
<SEC-HEADER>0001062993-24-019855.hdr.sgml : 20241202
<ACCEPTANCE-DATETIME>20241202100013
ACCESSION NUMBER:		0001062993-24-019855
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241202
FILED AS OF DATE:		20241202
DATE AS OF CHANGE:		20241202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Medicus Pharma Ltd.
		CENTRAL INDEX KEY:			0001997296
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42408
		FILM NUMBER:		241517647

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 3400
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
		BUSINESS PHONE:		(732) 300-3046

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 3400
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>

<head>
    <title>Medicus Pharma Ltd.: Form 6-K - Filed by newsfilecorp.com</title>
</head>

<body style="font-size:10pt; font-family:'Times New Roman';">
    <hr width="100%" size="3" color="black" noshade="noshade"><a name="page_1"></a>
    <p style="margin-bottom: 0pt; text-align: center;"><b><font size="5">UNITED STATES</font></b></p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b><font size="5">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;">Washington, D.C. 20549</p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;">&#160;</p>
    <p style="margin-top: 0pt; text-align: center;"><b><font size="5">Form 6-K</font></b></p>
    <p style="margin-bottom: 0pt; text-align: center;"><b>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE</b></p>
    <p style="margin-top: 0pt; text-align: center;"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>
    <p style="margin-bottom: 0pt; text-align: center;">For the month of <u><b>December 2024</b></u>.</p>
    <p style="margin-top: 0pt; text-align: center;">Commission File Number <u><b>001-42408</b></u></p>
    <p style="text-align: center;"><b><font size="5"><u>MEDICUS PHARMA LTD.</u></font></b><br>(Translation of registrant's name into English)</p>
    <p style="margin-bottom: 0pt; text-align: center;"><b>Suite 3400, 100 King St W</b></p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><u><b>Toronto, Ontario, Canada, M5X 1A4</b></u></p>
    <p style="margin-top: 0pt; text-align: center;">(Address of principal executive office)</p>
    <p style="margin-bottom: 0pt; text-align: justify;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p>
    <p style="text-align: center;">Form 20-F &#9746;<font style="width: 17.83pt; display: inline-block;">&#160;</font>Form 40-F &#9744;</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_2"></a>
    <p style="text-align: center;"><b>INDEX TO EXHIBITS</b></p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid rgb(0, 0, 0); width: 10%;">
                <p><b>Exhibit</b></p>
            </td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">
                <p>&#160;</p>
            </td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid rgb(0, 0, 0); width: 88%;">
                <p><b>Description</b></p>
            </td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: rgb(238, 238, 238); width: 10%;">
                <p><a href="exhibit99-1.htm">99.1</a></p>
            </td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: rgb(238, 238, 238); width: 2%;">&#160;</td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: rgb(238, 238, 238); width: 88%;">
                <p><a href="exhibit99-1.htm">Press release, dated December 2, 2024</a></p>
            </td>
        </tr>
    </table>
    <br>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_3"></a>
    <p style="text-align: center;"><b>SIGNATURES</b></p>
    <p style="text-indent: 36pt; text-align: justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%;">
                <p>&#160;</p>
            </td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 5%;">
                <p>&#160;</p>
            </td>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">
                <p><b>Medicus Pharma Ltd.</b></p>
            </td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%;">
                <p>&#160;</p>
            </td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 5%;">
                <p>&#160;</p>
            </td>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">
                <p>&#160;</p>
            </td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%;">
                <p>Date: December 2, 2024</p>
            </td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 5%;">
                <p>By</p>
            </td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000;">
                <p><i>/s/ Raza Bokhari</i></p>
            </td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%;">
                <p>&#160;</p>
            </td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 5%;">
                <p>&#160;</p>
            </td>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">
                <p>Name: Dr. Raza Bokhari</p>
            </td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%;">
                <p>&#160;</p>
            </td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 5%;">
                <p>&#160;</p>
            </td>
            <td style="vertical-align: middle;">
                <p style="margin-bottom: 0pt; margin-top: 0pt;">Title: Executive Chairman and Chief</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt;"><font style="width: 23.5pt; display: inline-block;">&#160;</font>Executive Officer</p>
            </td>
        </tr>
    </table>
    <br>
    <hr width="100%" size="5" color="black" noshade="noshade">
</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>

<head>
    <title>Medicus Pharma Ltd.: Exhibit 99.1 - Filed by newsfilecorp.com</title>
</head>

<body style="font-size:10pt; font-family:'Times New Roman';">
    <hr width="100%" size="3" color="black" noshade="noshade"><a name="page_1"></a>
    <p style="text-align: right;"><b>Exhibit 99.1</b></p>
    <p style="text-align: center;"><b><font size="5"><img src="exhibit99-1x001.jpg" style="width: 386px;" height="130"></font></b></p>
    <p style="text-align: center;"><b><font size="5">MEDICUS PHARMA LTD. ANNOUNCES COLLABORATION AGREEMENT TO EXPAND PHASE 2 CLINICAL STUDY IN ASIA PACIFIC REGION</font></b></p>
    <p style="text-align: center;"><b> </b><font style="font-size: 14pt;">PROVIDES UPDATE ON SKNJCT-003 PHASE 2 CLINICAL STUDY FOR TREATMENT OF NODULAR BASAL CELL CARCINOMA (BCC) CURRENTLY UNDERWAY IN UNITED STATES</font></p>
    <p style="text-align: justify;">Toronto, Ontario &amp; Philadelphia, PA - December 2, 2024 - Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce an agreement with Swanielle Inc. ("Swanielle") to explore expansion of Phase 2 clinical study for treatment of Basal Cell Carcinoma (BCC) in the Asia-pacific region.</p>
    <p style="text-align: justify; background-color: #ffffff;"><font style="color: #1d2228;">Under the agreement, Swanielle, a bespoke healthcare consulting firm, will help identify a pharmaceutical/biotech company or companies in Southeast Asia to partner with Medicus to expand the Phase 2 clinical study in the Asia Pacific region. </font></p>
    <p style="text-align: justify; background-color: #ffffff;"><font style="color: #1d2228;">The company is also pleased to announce that the phase 2 clinical study (SKNJCT-003) is currently underway in nine (9) clinical sites in United States and has already randomized more than 25% of the 60 patients expected to be enrolled in the study. Medicus is planning to initiate an interim data analysis in Q1 2025 and submit its findings to the United States Food and Drug Administration (FDA) as a part of a package seeking a Type C meeting with the FDA in Q2 2025. The purpose of the Type C meeting is to formally discuss the product development and gain further alignment on the clinical pathway. The Company's aim is to fast track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial.</font></p>
    <p style="text-align: justify;"><font style="color: #141414;"><b>Clinical Trial Design </b></font></p>
    <p style="text-align: justify;"><font style="color: #141414;">The clinical study, SKNJCT-003, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 60 subjects presenting with BCC of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. The participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100&#956;g of D-MNA, and a high-dose group receiving 200&#956;g of D-MNA.</font></p>
    <p style="text-align: justify;"><font style="color: #141414;">The high-dose, 200&#956;g D-MNA, proposed in the study is the maximum dose that was used in the Company's Phase 1 safety and tolerability study (SKNJCT-001) completed in March 2021. </font></p>
    <p style="text-align: justify;"><font style="color: #141414;">SKNJCT-001 met its primary objective of safety and tolerability. The investigational product, D-MNA was well-tolerated across all dose levels in all thirteen (13) participants enrolled in the study, with no dose-limiting toxicities (DLTs), or serious adverse events (SAEs). Furthermore, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examinations. The study also describes the efficacy of the investigational product, D-MNA, with 6 participants experiencing complete responses. The complete response is defined as the disappearance of BCC histologically in the final excision at the end of study visit. The participants profile demonstrating complete responses was diverse, and all participants (6/6) had nodular subtype of BCC.</font></p>
    <div id="footer_page_1">
        <p style="text-align: center;">- 1 -</p>
    </div>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_2"></a>
    <p style="text-align: justify;">"We are delighted with the progress we have made in advancing the clinical development program of our novel, non-invasive treatment to cure the most common cancer in the world," stated Dr. Raza Bokhari, Executive Chairman and CEO, "the collaboration with Swanielle to explore expansion of our clinical study to treat BCC in Southeast Asia will help us gather useful efficacy and safety data which will strengthen the analysis of the pivotal trial that we plan to commence in not-so-distant future".</p>
    <p style="text-align: justify; background-color: #ffffff;"><font style="color: #1d2228;">The agreement with Swanielle has an initial term of one year, commencing on December 1<sup>st</sup>, 2024. Under the agreement, Swanielle will receive a retainer fee of $22,500. In addition to the retainer, there is a variable rate success fee of 1%-5% dependent on the execution of a definitive agreement between company and a qualifying partner.</font></p>
    <p style="text-align: justify;">Swanielle does not have any interest, directly or indirectly, in the company or its securities, or any right or intent to acquire such an interest.</p>
    <p style="text-align: justify;"><b>For further information contact:</b></p>
    <p style="margin-bottom: 0pt; text-align: justify;">Carolyn Bonner, President</p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">(610) 636-0184</p>
    <p style="margin-top: 0pt; text-align: justify;"><font style="color: #0000ff;"><u>cbonner@medicuspharma.com</u></font></p>
    <p style="margin-bottom: 0pt; text-align: justify;">Jeremy Feffer</p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">LifeSci Advisors</p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">(212) 915-2568</p>
    <p style="margin-top: 0pt; text-align: justify;"><font style="color: #0000ff;"><u>jfeffer@lifesciadvisors.com</u></font></p>
    <div id="footer_page_2">
        <p style="text-align: center;">- 2 -</p>
    </div>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_3"></a>
    <p style="text-align: justify;"><font style="font-size: 12pt;"><i>About Medicus Pharma Ltd:</i></font></p>
    <p style="text-align: justify;"><i>Medicus Pharma Ltd. (Nasdaq: MDCX, TSXV: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. </i></p>
    <p style="text-align: justify;"><i>SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety &amp; tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company submitted a Phase 2 IND clinical protocol to the FDA in January 2024 for a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) that is expected to randomize up to 60 patients. The study is designed to evaluate the efficacy of two dose of two dose levels (100 and 200 ug) of D-MNA compared to placebo (P-MNA) in subjects with nodular BCC. Patient recruitment is currently underway in nine sites across the United States. </i></p>
    <p style="text-align: justify;"><u><i>Cautionary Notice on Forward-Looking Statements</i></u></p>
    <p style="text-align: justify;"><i>Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company's plans and expectations concerning, and future outcomes relating to, the collaboration agreement with Swanielle, and the submission and advancement of the phase 2 clinical protocol, including improvements thereto and the timing thereof, and approval from the FDA and the timing thereof. Forward-looking statements are often but not always, identified by the use of such terms as "may", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. </i></p>
    <p style="text-align: justify;"><i>These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on SEDAR+ and on EDGAR, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </i></p>
    <p style="text-align: justify;"><i>Readers are cautioned that the foregoing list is not exhaustive and readers are encouraged to review the Company's long form prospectus accessible on the Company's profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. </i></p>
    <p style="text-align: justify;"><i>Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.</i></p>
    <div id="footer_page_3">
        <p style="text-align: center;">- 3 -</p>
    </div>
    <hr width="100%" size="5" color="black" noshade="noshade">
</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exhibit99-1x001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit99-1x001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  0" P,# @0# P,$! 0$!0D&!04%
M!0L(" 8)#0L-#0T+# P.$!01#@\3#PP,$A@2$Q46%Q<7#A$9&QD6&A06%Q;_
MVP!# 00$! 4%!0H&!@H6#PP/%A86%A86%A86%A86%A86%A86%A86%A86%A86
M%A86%A86%A86%A86%A86%A86%A86%A;_P  1" "! 8(# 2(  A$! Q$!_\0
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MG_ \'_:KNI5)->\CZ7+\PKU;1K4VGW/?J*;&V]<[2OL:=70>V%%%% !1110
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MD<@9S7>O&CJ59<@C!!KQKQ)^SKX=E^,^E?$'PMJ%SX7N+20R7T&F*JK>'C
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M,ZY ]U/56'8C!':L+X$_#/0?A7X.D\/>'VNI(9;E[B66YEWO(S8'., 84*.
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MZL*^*9NN *^B?VY?#FN2>,K/Q%%;3W&E_8EMVDC4L('5V.&QT!W#FN0_9?\
MAC>>,/'-OJFI64B:)I<@FE>6,A;B0'*Q@GKS@M[#'<5VXA5*M?EL=&9TZV+Q
MZIVT1ROQN^&M]X%T/PWJ$ZR;=8L!)<;O^65Q]YD]L*R_DU>:2*S-M0%B<  #
M)-?HO\9_AYI?Q%\&OX?U%VMPKB6VN8P"\$H! 8 ]1@D$=P3TZUY'\+_V5[?0
M/&5OK>O>(8]3BL91+;VL5L8U=U.5,A+'(& <#J>^.#T2PDE)<NP\7D%5UU[)
M>Z?./QV^'&H?#N?1(K[<S:KIB7,A(XCF_P"6D7OMROYU:_9%\;Q>!_C?IMW>
M3"+3]2S87C,<*J.1M8GL X0D]AFOKW]J_P"&1^(WPP:SLEC&LZ>_VC3V9MH=
ML8:,D] R^O&0I[5^?.M65WIVH3V&H6TMM=6\ACFAE4J\; X((/0U4J;IRNC#
M&8667XJ-2"T/T_\ B#XFT[PKX%U7Q+J$H%MIMH\[#."^!PH]V. /4D5^6/BK
M5+K7/$5]K5\^^ZU"YDN9F]7=BQ_4UT.M>/?&FI>$T\,:AXFU*ZTB+;LLY;@M
M& N-HYZ@8& >!BN0FK9U.:Q689E];Y4E9(^P/^"57_(-\:_]=K+^4]?7%?(_
M_!*K_D&^-?\ KM9?RGKZXK>.Q]1E?^Z0"BBBJ/0/EO\ 8^Q_PUY\7_\ K\E_
M]*GKZ'^)7ABP\9>!-6\,ZDN;?4[.2W8XSL)'RN/=6PP]Q6!\.OA/X;\&?$3Q
M%XRTF>_>_P#$TK27J3RJT2EI"YV *".3W)KO&Y7%;UJJG44H^1E3IVARL_.[
MX8Z7XM\=^.O"_P !->1O[/\ "FM74UZH)XA5@9%/L"LBJW_385^AMK&L-ND2
M(J*BA551@ #L!7)^&_AOX;T3XJ:QX_LK9EU?7((X;IBP* )CE!C(+;5W<\[1
M7856*KJJURJR_4FC2<+WW/E'P[Q_P5*UW_L'+_Z;X*^K<?+7G]G\(?#EM\=K
MKXL)<:@=;NXO*DC,R_9PODK%PNW.=J#^+K7H!SMJ*U13<;=%8JE%QO?N?+'A
M=TC_ ."G6O&1U4?V4.2?^G6"OJ/[3;_\]X_^^Q7C?Q6_9D\ ?$'QW>^+=<O=
M<COK_P OS5M;J-(QL14& 8R>BCO7.?\ #&'PI')U+Q-_X&P__&JWG*A42<I-
M62Z&<8U(-V1]#FYMAUGC_P"^Q3X9(Y5W1NK '&0:^=?^&,/A3_T$O$W_ (&P
M_P#QJO7?@G\.M$^%_@O_ (1GP_->2V?VE[C==R*\FYL9Y50,<#M6%2-)+W)7
M?H:1E-OWD>2?\%-N/V>[0_\ 4>M__14U>[>%[FW'AK3\SQ_\>D7\8_N"N?\
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M110 48'I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
